SI-6603
Not specified in provided content
Regulatory submissionActive (U.S. application resubmitted March 2026)
Key Facts
Indication
Not specified in provided content
Phase
Regulatory submission
Status
Active (U.S. application resubmitted March 2026)
Company
About Seikagaku
Japanese glycoscience pioneer developing hyaluronic acid-based therapeutics for ophthalmology and orthopedics, with commercial products and late-stage pipeline.
View full company profile